The 40:1 inositol ratio, explained

If you have looked at PCOS supplements, you have seen the number: 40:1 myo-inositol to D-chiro-inositol. It appears on nearly every product in the category, usually presented as the physiological ratio, sometimes as the clinically proven one.

The uniformity is striking and it makes the figure look settled. It rests on a narrower basis than most people assume.

If you are formulating in this category, or paying a premium for the ratio, here is what it actually comes from.

This is information, not medical advice. PCOS management should be directed by your doctor. Do not change a prescribed treatment on the basis of an article.

The two molecules

Inositol is a sugar alcohol, present in food, fruit, beans, grains and nuts, and also synthesised by the body. It functions as a precursor for molecules involved in insulin signalling, which is why it reaches PCOS at all, since insulin resistance sits at the centre of the condition.

Myo-inositol (MI) is the most abundant form in the body. In the ovary it is involved in FSH signalling and, by extension, in follicle development and oocyte quality.

D-chiro-inositol (DCI) is made from myo-inositol by an enzyme, epimerase. It is involved in insulin-mediated glucose disposal and in androgen synthesis in the ovary.

The two are not interchangeable, they appear to do different jobs in different tissues, which is the whole reason a ratio question exists.

Where 40:1 comes from

The ratio is derived from a specific observation: the approximate ratio of myo-inositol to D-chiro-inositol in human plasma was reported at around 40:1.

The reasoning then runs: the body’s own plasma ratio is 40:1, therefore supplementing at 40:1 is physiological, therefore it is optimal.

Two trials in particular compared a 40:1 formulation against other ratios and against myo-inositol alone, and reported that 40:1 performed better on ovulation and hormonal measures. Those studies are what the “clinically proven” phrasing in marketing refers to.

So the figure is not invented. It has a stated rationale and some supporting trial work.

Why the basis is weaker than it looks

Three problems, and they are worth understanding before paying a premium.

First, plasma ratio is not the same as tissue ratio. The 40:1 figure describes circulating blood. Different tissues concentrate these molecules differently, the ovary in particular handles them differently from plasma, which is the entire basis of the “ovarian paradox” discussion in this literature. Matching the plasma ratio is an assumption about relevance, not a demonstration of it.

Second, the dose and the ratio are confounded. The standard 40:1 product delivers 2000 mg MI with 50 mg DCI, twice daily, around 4000 mg of myo-inositol a day in total. That myo-inositol dose is also what most of the single-ingredient trials used.

So when a 40:1 product works, it is difficult to separate the contribution of the ratio from the contribution of the 4000 mg of myo-inositol. The comparisons that would settle this cleanly, same MI dose, different DCI amounts, adequately powered, are thin on the ground.

Third, and most important: the bulk of the clinical evidence in PCOS is for myo-inositol, not for the ratio. Trials and meta-analyses examining inositol in PCOS have largely studied myo-inositol, often alone or with folic acid, reporting improvements in ovulation, menstrual regularity and some metabolic and hormonal measures. The evidence base for 40:1 specifically being superior is considerably smaller than the near-universal adoption of the number implies.

Which leads to an honest summary: myo-inositol at around 4 g daily has reasonable supporting evidence in PCOS. Whether adding DCI at exactly 1/40th improves on that is plausible, under-tested, and not established. The ratio became a standard partly on evidence and partly because the first products used it and the rest followed.

What the evidence does support

Being specific, because this matters more than the ratio debate.

Reasonably supported for myo-inositol in PCOS:

• Improved ovulation rates and menstrual regularity
• Improvements in insulin sensitivity measures
• Some improvement in hormonal parameters, including androgens in some studies
• Use in IVF protocols, with interest in oocyte quality
• A good safety and tolerability profile, adverse effects are mild and uncommon at usual doses, mostly gastrointestinal at higher ones

Caveats that belong with that list: many trials are small, quality varies, several are industry-funded, and outcome measures differ enough between studies to make pooling difficult. This is a promising body of evidence, not a settled one.

Versus metformin: several studies have compared them, generally finding broadly comparable effects on some outcomes with better tolerability for inositol, metformin’s gastrointestinal side effects cause real adherence problems. This is a genuine point in inositol’s favour and a reasonable thing to discuss with a doctor.

But: metformin has decades of use, much larger trial data, and is inexpensive. Inositol is a supplement, not a replacement for prescribed treatment, and swapping one for the other is a medical decision.

Practical formulation numbers

For anyone specifying a product:

	Typical specification
Myo-inositol	2000 mg, twice daily (4 g/day total)
D-chiro-inositol	50 mg, twice daily (at 40:1)
Folic acid	Commonly included, 200–400 mcg
Form	Powder/sachet or large capsules
Duration in trials	3–6 months

The format problem is real and worth planning for. Four grams a day is a lot of material. It does not fit into a reasonable number of capsules, so this category is naturally a powder or sachet product. Clients who ask for a two-capsule-a-day version are usually asking for an underdosed product, and an underdosed inositol product is one where the evidence no longer applies.

That is the most common specification error we see in this category: the dose gets cut to fit the format, and then the label cites research conducted at the full dose.

Cost note: myo-inositol is comparatively inexpensive. D-chiro-inositol is considerably more expensive per kilogram, but at 1/40th the quantity, its contribution to cost is modest. So the 40:1 version is not dramatically costlier than myo-inositol alone, which is part of why it persists: it is cheap to include and it gives the label a number.

Side by side

	Myo-inositol alone	40:1 MI:DCI
Evidence volume in PCOS	Larger	Smaller, specific to the ratio
Rationale	Direct; the most-studied form	Matches reported plasma ratio
Typical dose	4 g/day	4 g MI + 100 mg DCI
Cost	Lower	Slightly higher
Market expectation	Less recognised now	The de facto standard
Honest status	Reasonable evidence	Plausible, under-tested

How to decide

If you are formulating: use 40:1 at the proper dose. Not because the ratio is proven superior, but because it is the market standard, buyers expect it, the added cost is small, and the DCI contribution is plausible. The thing that actually matters is delivering the full 4 g of myo-inositol, get that right and the ratio question is secondary.

If you are buying: check the myo-inositol quantity per day, not the ratio on the front of the pack. A product proudly labelled 40:1 that delivers 1 g of myo-inositol daily is not the thing the research studied. The ratio is marketing; the dose is the active decision.

And check what else is in it. Inositol products sometimes arrive padded with small quantities of many ingredients, which raises cost without raising effect.

If you have PCOS: discuss it with your doctor, particularly if you are already on metformin or hormonal treatment. Give it three to six months, which is what the trials ran for, and judge it on something measurable, cycle length, whether ovulation is occurring, rather than on how you feel.

What cannot be claimed

We manufacture in this category, so the line matters.

Not sayable: treats PCOS; regulates periods; restores ovulation; improves fertility; balances hormones; a natural alternative to metformin. All of these are medicinal claims, and in India several fall under the Drugs and Magic Remedies (Objectionable Advertisements) Act, which specifically restricts advertising relating to conception.

Sayable: inositol’s role as a nutrient; folate’s recognised role in normal cell division and maternal tissue growth; traditional use of the Ayurvedic herbs where included; general wellness support.

And the clinical point we ask clients to carry: prolonged absence of periods is a medical concern in its own right, because unopposed endometrial proliferation over years raises risk. Someone managing PCOS with a supplement and no periods for eight months should be speaking to a doctor, not reordering. That belongs on the artwork.

The short version

40:1 comes from the reported myo-inositol to D-chiro-inositol ratio in human plasma, plus a small number of comparative trials. It is a reasonable rationale, not a settled finding.

The bulk of PCOS evidence is for myo-inositol itself, at around 4 g daily. Whether 1/40th DCI improves on that is plausible and under-tested, and the dose and ratio are confounded in most of the research.

So the number that matters when you buy is the myo-inositol quantity per day, not the ratio on the label. Four grams a day means a powder or sachet; a two-capsule product is almost certainly underdosed.

Composition detail: Ovario 360. On diet, which does more than any supplement here: PCOD में क्या खाएँ और क्या नहीं.